Plasmodium Falciparum: Increased Proportion of Severe Resistance (RII and RIII) to Chloroquine and High Rate of Resistance to Sulfadoxine-Pyrimethamine in Peninsular Malaysia After Two Decades

Trans R Soc Trop Med Hyg. May-Jun 1996;90(3):294-7. doi: 10.1016/s0035-9203(96)90258-8.

Abstract

Uncomplicated falciparum malaria patients were randomly assigned to receive either 25 mg/kg chloroquine (CHL) over 3 d or a statim dose of 25 mg/kg sulfadoxine (SDX) plus 1.25 mg/kg pyrimethamine (PYR). Patients were followed up for 28 d and the parasite response graded according to World Health Organization criteria. Overall resistance to CHL was 63.3% and 47.4% to SDX/PYR. RI, RII and RIII rates were 9.1%, 42.4% and 12.1% for CHL and 10.5%, 21.1% and 15.8% for SDX/PYR, respectively. Degree and rates of resistance to CHL were significantly correlated with pre-treatment parasite density, but not those to SDX/PYR. Plasma CHL and SDX/PYR levels were within the reported ranges and were not significantly different in patients with sensitive and resistant responses.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antimalarials / blood
  • Antimalarials / therapeutic use*
  • Child
  • Child, Preschool
  • Chloroquine / blood
  • Chloroquine / therapeutic use*
  • Drug Combinations
  • Drug Resistance, Multiple*
  • Female
  • Follow-Up Studies
  • Humans
  • Malaria, Falciparum / blood
  • Malaria, Falciparum / drug therapy*
  • Malaysia
  • Male
  • Middle Aged
  • Parasitemia / drug therapy
  • Prospective Studies
  • Pyrimethamine / blood
  • Pyrimethamine / therapeutic use*
  • Sulfadoxine / blood
  • Sulfadoxine / therapeutic use*

Substances

  • Antimalarials
  • Drug Combinations
  • fanasil, pyrimethamine drug combination
  • Sulfadoxine
  • Chloroquine
  • Pyrimethamine